Added to YB: 2026-05-12
Pitch date: 2026-05-08
NOVO-B.CO [neutral]
Novo Nordisk A/S
+1.87%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 294.50
Price Target
N/A
Dividend
4.03%
EV/EBITDA
8.04
P/E
10.59
EV/Sales
4.31
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 8/5/2026 - NOVOB – Q1 beat and raise
NOVO-B.CO (earnings): Q1 adj sales 70bn DKK (-4% CER), op profit 33bn DKK (-6% CER, 46.9% margin) beat low expectations. US sales -11%, RoW +6%. Oral Wegovy reached 1M US users. FY guide raised to -4% to -12% sales/op profit (vs -5% to -13%). Q1 FCF 12.8bn DKK. Serves 45M patients (~0.5% global pop). Trades 13.5x 2027 EPS, 3.9% yield—potential re-rating if topline growth returns.
Read full article (2 min)